SYRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. SYRE just sold off (-4.8% regular session) and short-term momentum is weakening (MACD histogram negative and expanding). While the longer-term trend still looks constructive (SMA_5 > SMA_20 > SMA_200) and Wall Street initiation notes are very bullish, options positioning is skewed heavily to puts (OI put/call 3.4), suggesting cautious-to-bearish near-term sentiment/hedging. With no near-term news catalyst and a pre-revenue, loss-making profile, the current setup doesn’t favor immediate upside follow-through from here—better to hold off until momentum stabilizes above the pivot (33.24) or a clear catalyst emerges.
Price/Trend: Post-market ~31.96 after a -4.76% regular-session drop; trading below the pivot (33.243) and sitting right on key support S1 (31.89) with the next support at S2 (31.054). Momentum: MACD histogram -0.115 and negatively expanding = bearish momentum increasing. RSI(6) ~39.6 = weak/near-oversold but not a clear reversal signal. Moving averages: SMA_5 > SMA_20 > SMA_200 = longer-term uptrend structure remains intact, but the latest selloff suggests a near-term pullback within that trend. Immediate levels: A clean reclaim of 33.24 would improve the near-term setup; failure to hold 31.89 raises odds of testing ~31.05.
Intellectia Proprietary Trading Signals
Recent bullish Street initiations: Mizuho (Outperform, $53 PT) and Citi (Buy, $64 PT) citing best-in-class antibody potential and future inflection points. Longer-term technical structure still bullish via moving averages (SMA_5 > SMA_20 > SMA_200). Potential event-driven upside later from pipeline data readouts discussed for 2026–2027 (per analyst commentary).
No news catalyst in the past week to arrest the selloff; near-term move is momentum-driven lower. Bearish/defensive options positioning (put/call OI 3.4). Short-term momentum deterioration (MACD negative and worsening) with price below pivot and pressing support (~31.89). Similar-pattern projection indicates modest upside next week but negative bias next month (-4.44%), aligning with a choppy-to-down near-term risk.
Latest quarter: 2025/Q3. Revenue remains 0 (pre-commercial biotech). Losses worsened materially: Net income -$11.18M (down ~83.8% YoY), EPS -0.19 (down ~86.0% YoY). This is consistent with increased R&D spend/operating ramp and means the stock is primarily catalyst- and sentiment-driven rather than fundamentals-driven in the near term.
Analyst trend: two new initiations (both on 2025-12-17) with bullish ratings and high price targets—Mizuho Outperform $53 and Citi Buy $64. Wall Street pros: strong enthusiasm for the half-life extended monoclonal antibody platform, combination potential in IBD/autoimmune, and perceived upside into future data readouts. Cons: timelines are longer-dated (2026–2027 inflections), and without nearer-term catalysts the stock can trade on risk-off moves; also pre-revenue with widening losses, increasing reliance on sentiment and funding expectations.
